mRNA vaccine may boost immunotherapy for lung cancer

Fascinating early evidence suggesting that mRNA COVID vaccines might enhance the efficacy of immunotherapy in lung cancer. It highlights how immune modulation from vaccines could have unexpected benefits beyond infection prevention. Looking forward to seeing these findings validated in larger clinical studies.

PD-1 blockade has transformed cancer therapy. But its success depends on demonstrating target engagement in patients. Receptor occupancy assays are the standard tool, yet they are not trivial to establish. Variability in receptor expression, receptor internalization, and shifts in baseline levels can obscure results and delay development. To overcome these challenges, our senior scientists developed an occupied format RO assay that: ✅ Normalizes variability with total receptor ✅ Intra-run CV as low as 0.78% ✅ Inter-run CV consistently < 7.3% ✅ Delivers drug-dependent linearity 𝗡𝗼𝘄 𝗮𝗽𝗽𝗹𝗶𝗲𝗱 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗱𝘆𝗻𝗮𝗺𝗶𝗰 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗣𝗗-𝟭 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀. 🔗 Download the full case study: https://lnkd.in/dZbyAEz8 #CrystalBioSolutions #Immunology #Oncology #ClinicalPharmacology

Cancer patients who got a COVID vaccine lived much longer https://flip.it/AMHguA A groundbreaking study reveals that cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy lived dramatically longer than those who didn’t.

Bladder Cancer: What can we do to further improve outcomes for patients with bladder cancer who are treated with Immune Checkpoint Inhibitors? Voltron’s VTX-0P4 delivers a potent and broad immune response to target tumors expressing PSCA including bladder. Immune activating VTX-0P4 achieved positive preclinical results when used alone or in combination with an immune checkpoint inhibitor. VTX-0P4 showed significant improvement in survival and tumor reduction. VTX-0P4 in combination with an immune checkpoint inhibitor has the potential to improve patient outcomes. Voltron’s technology platform drives the engagement and activation of multiple components of the body’s immune system designed to improve patient outcomes, addressing the limitations of current therapies. preserveandserve.com Keytruda.com mylife.org insidebladdercancer.com bcan.org Voltrontx.com #bladdercancer #HPVrelatedcancers #AmericanCancerSociety #ImmuneActivation #VoltronTherapeutics #VTX-0P4 #keytruda #bladdercancer

Breakthrough study by the University of Florida shows that an mRNA COVID-19 vaccine, when given within ~100 days of starting immunotherapy, is associated with nearly double the median survival in advanced lung and skin cancer patients receiving checkpoint inhibitors. #immunotherapy #cancervaccine #mRNA #oncology https://lnkd.in/e9Qx-Y5F

The same Nobel-winning mRNA technology that helped curb Covid-19 may be poised to transform cancer care. A new study in Nature from the University of Florida and UT MD ANDERSON CANCER CENTER found that cancer patients who received an #mRNA Covid vaccine around the start of #immunotherapy lived significantly longer than those who didn’t. In lung and skin cancers, survival nearly doubled — and scientists think they know why. The mRNA platform seems to amplify the immune system’s “early alert” response, working in tandem with checkpoint inhibitors like Keytruda and Opdivo. If confirmed, this could mark a new era for cancer immunotherapy — and even point toward a universal, off-the-shelf cancer vaccine. https://lnkd.in/gRSAmumb

COVID-19 mRNA vaccines may have extra benefits for cancer patients.  Late-state melanoma and lung cancer patients who received the Pfizer or Moderna mRNA vaccines within 100 days of starting immunotherapy were more than twice as likely to be alive after three years compared with those who didn’t receive either vaccine. The University of Texas MD Anderson Cancer Center's Adam Grippin and University of Florida's Christiano Marconi explain their research into how mRNA fights tumors: https://lnkd.in/eqDSv2wm

Could COVID mRNA vaccines make cancer immunotherapy more effective? A new study reveals these vaccines trigger a powerful interferon-driven immune surge, potentially transforming resistant \"cold\" tumors into targets for immune checkpoint therapy in lung and skin cancers. Explore how widely available mRNA vaccines might pave the way for more effective, scalable cancer treatments - and why these findings could change the future of oncology \(pending further validation\). https://lnkd.in/g2ehvVNQ \#CancerResearch \#Immunotherapy \#MRNAVaccines

Revolutionary Cancer Vaccine Eliminates Deadly Brain Tumor A groundbreaking cancer vaccine has stunned the medical world by completely eradicating a deadly brain tumor — without chemotherapy or radiation. Instead, the patient’s immune system was trained to recognize and destroy cancer cells, leaving healthy tissue unharmed. This breakthrough offers a safer, more precise alternative to traditional treatments, which often cause devastating side effects. Researchers are now expanding trials to test the vaccine on more patients and other aggressive brain tumors. If results hold, this could transform the future of cancer treatment and give hope to millions who face limited options today. While still in early stages, this breakthrough marks a monumental leap in immunotherapy — potentially opening the door to universal cancer-fighting vaccines. #CancerVaccine #BrainTumorCure #MedicalBreakthrough #Immunotherapy #FutureOfMedicine #medical #HealthResearch

Mark L. Gordon, M.D. Fox News TV What if a single shot could train your immune system to hunt down cancer cells? That’s exactly what scientists are working on — and early results are incredible. New mRNA-based cancer vaccines, developed by companies like BioNTech and Moderna, are showing the ability to trigger long-lasting immune responses. In clinical trials, some patients — especially those with melanoma — have remained cancer-free for over 3 years after treatment. These vaccines use personalized tumor blueprints to teach your body what to attack — making cancer treatment smarter, targeted, and possibly preventive in the future. We’re not there yet, but we’re closer than ever. This could be the beginning of the end for certain types of cancer. #CancerVaccine #mRNA #MedicalBreakthrough #CancerFree #Immunotherapy #Moderna #BioNTech #FutureOfMedicine #Oncology #HopeThroughScience #PersonalizedMedicine #MelanomaResearch #CancerSurvivor